Selexis SA, a JSR Life Sciences company, has signed a service agreement with Pandion Therapeutics, Inc. to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Pandion will leverage Selexis’ proprietary SUREtechnology Platform to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.
 
Selexis’ modular SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines, providing seamless integration of the development continuum from discovery to commercialization.
 
“Pandion’s selection of Selexis as a cell line development partner is a testament to the value of our SUREtechnology Platform, which we designed to address the challenges of achieving high expression levels for antibodies,” said Yemi Onakunle, PhD, MBA, Selexis chief business officer. “In the context of today’s pandemic environment, in which many manufacturing resources are going towards production of COVID-19 vaccines and antibodies, every advantage in drug development is critical.”
 
“We chose to work with Selexis for both the expertise of its scientists, and also because the Company’s technology platform allows for high performance, predictability and versatility in cell line development,” said Nathan Higginson-Scott, VP, research and head of biotherapeutics, Pandion Therapeutics.